Alonso-Peña, Marta
Dierssen, Trinidad
Marin, Maria José
Alonso-Molero, Jessica
Gómez-Acebo, Inés
Santiuste, Inés
Lazarus, Jeffrey V.
Sanchez-Juan, Pascual
Peralta, Galo
Crespo, Javier
Lopez-Hoyos, Marcos
Peleteiro-Vigil, Ana
Lavin Gomez, Bernardo Alio
Alvaro Melero, Olga
Arias-Loste, Maria Teresa
Batlle, Ana
Cabezas, Joaquin
Calvo Montes, Jorge
Cayon de las Cuevas, Joaquín
Conde, Laura
Diego Gonzalez, Lara
Fariñas, Carmen
Fernandez Luis, Sara
Fernandez Ortiz, Maria
Garcia Blanco, Santiago
Garcia Lopez, Gema
Garcia Unzueta, Maite
Garrido Gomez, Jose Carlos
Gonzalez, Raquel
Iruzubieta, Paula
Martin Lazaro, Jesus
Martin Ruiz, Lucia
Martinez Magunacelaya, Nerea
Martinez Santiago, Raul
Medina, Juan Manuel
Muruzabal Siges, Maria Josefa
Padilla, Ana
Peleteiro, Ana
Reyes-González, Luis
Ruiz, David
Santos-Laso, Alvaro
Sanz Piña, Maria Elena
Sordo, David
Solorzano, Sergio
Tejido, Rafael
Wallman, Reinhard
Wunsch, María
,
Article History
Received: 25 May 2023
Accepted: 23 November 2023
First Online: 5 December 2023
Declarations
:
: This study protocol (ID 2021.057) was approved by the Ethics Committee for Drug Research of Cantabria on 26 February 2021. The study respects the ethical principles of research with biological samples, the 1975 Declaration of Helsinki and Spanish Law 14/2007, of July 3, 2007, on Biomedical Research.Informed consent will be obtained from all subjects included in the study and/or their legal guardian(s). It can be consulted, together with the participant’s information sheet, at ExternalRef removed.
: Not applicable.
: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Nonetheless, they stated that: M.A.P. received a fellowship from Hoffmann-La Roche; J.V.L. reports grants from AbbVie, Gilead Sciences, MSD, and Roche Diagnostics; consulting fees from Novo-Vax; payment or honoraria for lectures, presentations, speakers’ bureaus, and educational events from AbbVie, Gilead, Sciences, Intercept, and Janssen; M.L.H. reports grants from Werfen and ThermoFisher; consulting fees from Werfen and ThermoFisher; payment or honoraria for lectures, presentations, speakers’ bureaus, and educational events from Werfen, ThermoFisher, Sanofi, GSK, Astra Zeneca, UCB Pharma, Astellas, and Takeda. The rest of the authors have no competing interest to declare.